{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:28Z","timestamp":1788825628032,"version":"build-2803163510"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Despite progress in understanding the biology of adrenocortical carcinoma (ACC), treatment options have not dramatically changed in the last three decades, nor have we learned how to avoid some of its long-term side effects. Our goal was to improve the understanding of immune pathways that may include druggable targets to enhance immune responses of patients with ACC, focusing on immune evasion and the activation of immune cells against ACC. Our strategy was aimed at improving insight regarding gene expression without steroid interference. Using approaches based on high and low steroid phenotypes (HSP and LSP, respectively), we characterized immune pathways using The Cancer Genome Atlas (TCGA) ACC cohort data. Although previous studies have suggested that patients with ACC receive minimal benefit from immunotherapy, high expression of immune modulators was noted in patients with LSP, suggesting the activation of these biomarkers may be an important adjuvant therapy target after clearance of excess glucocorticoids. In addition, patients with LSP ACC had higher immune cell infiltration than patients with HSP ACC and other cancer subtypes. Our findings can be summarized as follows (1): we confirmed and improved the definition of two immune response pathways to ACC (HSP and LSP) based on <jats:italic>in silico<\/jats:italic> transcriptome analysis (2), we demonstrated the steroid profile should be considered, otherwise analyses of ACC immune characteristics can generate confounding results (3), among the overexpressed immunotherapy targets, we demonstrated that LSP was rich in <jats:italic>PDCD1LG2<\/jats:italic> (<jats:italic>PD-L2)<\/jats:italic> and both HSP and LSP overexpressed <jats:italic>CD276<\/jats:italic> (<jats:italic>B7-H3)<\/jats:italic>, which was associated with resistance to anti-PD1 therapy and may have accounted for the modest results of previous clinical trials, and (4) identification of patients with LSP or HSP ACC can be used to help determine whether immunotherapy should be used. In conclusion, we highlighted the differences between LSP and HSP, drawing attention to potential therapeutic targets (<jats:italic>CD276<\/jats:italic>, <jats:italic>PDCD1<\/jats:italic>, and <jats:italic>PDCD1LG2<\/jats:italic>). Treatments to reduce immune evasion, as well as the use of other natural and pharmacological immune activators, should include prior pharmacological inhibition of steroidogenesis. Attempts to combine these with tumor cell proliferation inhibitors, if they do not affect cells of the immune system, may produce interesting results.<\/jats:p>","DOI":"10.3389\/fendo.2021.672319","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T14:56:56Z","timestamp":1623682616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Adrenocortical Carcinoma Steroid Profiles: In Silico Pan-Cancer Analysis of TCGA Data Uncovers Immunotherapy Targets for Potential Improved Outcomes"],"prefix":"10.3389","volume":"12","author":[{"given":"Jo\u00e3o C. D.","family":"Muzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Magno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena A.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"de Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro A. A.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonald C.","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2639","article-title":"Adrenocortical Carcinoma: Clinical Update","volume":"91","author":"Allolio","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1677\/erc.1.01130","article-title":"Adrenocortical Cancer: Pathophysiology and Clinical Management","volume":"14","author":"Lib\u00e8","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3020","article-title":"Update in Adrenocortical Carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic Role of Overt Hypercortisolism in Completely Operated Patients With Adrenocortical Cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0221-7","article-title":"Adrenocortical Carcinoma \u2014 Towards Genomics Guided Clinical Care","volume":"15","author":"Crona","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6072863","DOI":"10.1155\/2019\/6072863","article-title":"Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma","volume":"2019","author":"Fiorentini","year":"2019","journal-title":"J Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival","volume":"27","author":"de Reyni\u00e8s","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1067","article-title":"Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling","volume":"15","author":"Giordano","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive Analyses of Tumor Immunity: Implications for Cancer Immunotherapy","volume":"17","author":"Li","year":"2016","journal-title":"Genome Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e000469","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay Between Glucocorticoids and Tumor-Infiltrating Lymphocytes on the Prognosis of Adrenocortical Carcinoma","volume":"8","author":"Landwehr","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.085","article-title":"Clinical and Outcome Characteristics of Children With Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry","volume":"22","author":"Michalkiewicz","year":"2004","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111730","article-title":"The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, Pd-1, PD-L1, and the Weiss Score","volume":"11","author":"Parise","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1038\/ncomms7302","article-title":"Genomic Landscape of Paediatric Adrenocortical Tumours","volume":"6","author":"Pinto","year":"2015","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072739","article-title":"Cancer Immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.mce.2011.10.019","article-title":"Molecular Epidemiology of Adrenocortical Tumors in Southern Brazil","volume":"351","author":"Cust\u00f3dio","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0450","article-title":"Influence of Hormonal Functional Status on Survival in Adrenocortical Carcinoma: Systematic Review and Meta-Analysis","volume":"179","author":"Vanbrabant","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2015.00023","article-title":"Pediatric Adrenocortical Tumors: What They Can Tell Us on Adrenal Development and Comparison With Adult Adrenal Tumors","volume":"6","author":"Lalli","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181454","article-title":"NK Cells Switch From Granzyme B to Death Receptor\u2013Mediated Cytotoxicity During Serial Killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0500","article-title":"A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients","volume":"7","author":"Cursons","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","article-title":"Breathing New Life Into Immunotherapy: Review of Melanoma, Lung and Kidney Cancer","volume":"11","author":"Drake","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01460","article-title":"In Vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant Bcg Strain for Bladder Cancer Treatment","volume":"10","author":"Rodriguez","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG Immunotherapy and its Outlook for Bladder Cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7150\/jca.30723","article-title":"Aging, Cancer and Immunity","volume":"10","author":"Hong","year":"2019","journal-title":"J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.09.010","article-title":"Towards an Understanding of the Role of p53 in Adrenocortical Carcinogenesis","volume":"351","author":"Wasserman","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0361-7","article-title":"B7-H7 (HHLA2) Inhibits T-cell Activation and Proliferation in the Presence of TCR and CD28 Signaling","author":"Rieder","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 Family Revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"Pd-1 Blockade in Advanced Adrenocortical Carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Adrenocortical Carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in Patients With Previously Treated Metastatic Adrenocortical Carcinoma: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0398","article-title":"Immunotherapy Failure in Adrenocortical Cancer: Where Next","volume":"7","author":"Cosentini","year":"2018","journal-title":"Endocr Connect"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"Tcgabiolinks: An R\/Bioconductor Package for Integrative Analysis of TCGA Data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.12688\/f1000research.8923.2","article-title":"Tcga Workflow: Analyze Cancer Genomics and Epigenomics Data Using Bioconductor Packages","volume":"5","author":"Silva","year":"2016","journal-title":"F1000Research"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1006701","DOI":"10.1371\/journal.pcbi.1006701","article-title":"New Functionalities in the TCGAbiolinks Package for the Study and Integration of Cancer Data From GDC and Gtex","volume":"15","author":"Mounir","year":"2019","journal-title":"PloS Comput Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: Digitally Portraying the Tissue Cellular Heterogeneity Landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz363","article-title":"Comprehensive Evaluation of Transcriptome-Based Cell-Type Quantification Methods for Immuno-Oncology","volume":"35","author":"Sturm","year":"2019","journal-title":"Bioinformatics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust Enumeration of Cell Subsets From Tissue Expression Profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"B42","article-title":"Summarizedexperiment: SummarizedExperiment Container","volume-title":"R package version 1.20.0","author":"Morgan","year":"2020"},{"key":"B43","article-title":"Annotationhub: Client to Access AnnotationHub Resources","volume-title":"R package, version 2.22.0","author":"Morgan","year":"2020"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated Estimation of Fold Change and Dispersion for RNA-seq Data With Deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2007.12.007","article-title":"Ifn-\u03b2-Regulated Genes Show Abnormal Expression in Therapy-Na\u00efve Relapsing\u2013Remitting MS Mononuclear Cells: Gene Expression Analysis Employing All Reported Protein\u2013Protein Interactions","volume":"195","author":"Yamaguchi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7287\/peerj.preprints.2420","article-title":"Tmod: An R Package for General and Multivariate Enrichment Analysis","volume":"4","author":"Weiner","year":"2016","journal-title":"PeerJ"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz447","article-title":"Gene Set Enrichment for Reproducible Science: Comparison of CERNO and Eight Other Algorithms","volume":"35","author":"Zyla","year":"2019","journal-title":"Bioinformatics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database Hallmark Gene Set Collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"B50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular Signatures of Antibody Responses Derived From a Systems Biology Study of Five Human Vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/s41467-020-19540-z","article-title":"Biomaterial-Based Scaffold for in Situ Chemo-Immunotherapy to Treat Poorly Immunogenic Tumors","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1038\/ncomms8866","article-title":"A Draft Network of Ligand\u2013Receptor-Mediated Multicellular Signalling in Human","volume":"6","author":"Ramilowski","year":"2015","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/gb-2012-13-4-r29","article-title":"Reder: R\/Bioconductor Package for Representing Modular Structures, Nested Networks and Multiple Levels of Hierarchical Associations","volume":"13","author":"Castro","year":"2012","journal-title":"Genome Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors From 33 Types of Cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"B55","article-title":"A Package for Survival Analysis in R","volume-title":"R package version 3.2-7","author":"Therneau","year":"2020"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"B57","volume-title":"Qvalue: Q-value Estimation for False Discovery Rate Control R Package Version 2.22.0","author":"Storey","year":"2020"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","article-title":"Rna-Seq Signatures Normalized by Mrna Abundance Allow Absolute Deconvolution of Human Immune Cell Types","volume":"26","author":"Monaco","year":"2019","journal-title":"Cell Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.surg.2018.04.086","article-title":"Expression of Programmed Death Ligand 1 and 2 in Adrenocortical Cancer Tissues: An Exploratory Study","volume":"165","author":"Tierney","year":"2019","journal-title":"Surgery"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5354825","article-title":"Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma","volume":"2020","author":"Liang","year":"2020","journal-title":"Dis Markers"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: An Attractive Target for Antibody-based Immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in Cancer \u2013 Beyond Immune Regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2852","article-title":"B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity","volume":"24","author":"Yonesaka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/683875","article-title":"B7-H3 and Its Role in Antitumor Immunity","volume":"2010","author":"Loos","year":"2010","journal-title":"Clin Dev Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9502-1","article-title":"Significance of Heparanase-1 and Vascular Endothelial Growth Factor in Adrenocortical Carcinoma Angiogenesis: Potential for Therapy","volume":"40","author":"Xu","year":"2011","journal-title":"Endocrine"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-017-0259-6","article-title":"Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors","volume":"24","author":"Pereira","year":"2018","journal-title":"Pathol Oncol Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF Inhibitor Axitinib has Limited Effectiveness as a Therapy for Adrenocortical Cancer","volume":"99","author":"O\u2019Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II Study of Weekly Paclitaxel and Sorafenib as Second\/Third-Line Therapy in Patients With Adrenocortical Carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s40425-019-0744-4","article-title":"BTLA Blockade Enhances Cancer Therapy by Inhibiting IL-6\/IL-10-induced Cd19high B Lymphocytes","volume":"7","author":"Chen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104622","article-title":"Interleukin-10 and Related Cytokines and Receptors","volume":"22","author":"Pestka","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00583-9","article-title":"In Silico Transcriptomic Mapping of Integrins and Immune Activation in Basal-like and HER2+ Breast Cancer","author":"Rojas","year":"2021","journal-title":"Cell Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.82","article-title":"4-1BB Signaling Beyond T Cells","volume":"8","author":"Vinay","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy Targeting 4-1BB: Mechanistic Rationale, Clinical Results, and Future Strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11912-019-0773-7","article-title":"Management of Adrenocortical Carcinoma","volume":"21","author":"Jasim","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2953","article-title":"Integrated Genomic Characterization of Adrenocortical Carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.3.5526","article-title":"Comparative Genomic Hybridization Analysis of Adrenocortical Tumors of Childhood 1","volume":"84","author":"Figueiredo","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B77","article-title":"Genetic Aberrations in Adrenocortical Tumors Detected Using Comparative Genomic Hybridization Correlate With Tumor Size and Malignancy","volume":"56","author":"Kjellman","year":"1996","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"711723","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival With Ipilimumab in Patients With Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000212965.52759.1c","article-title":"Mitotane Associated With Cisplatin, Etoposide, and Doxorubicin in Advanced Childhood Adrenocortical Carcinoma","volume":"28","author":"Zancanella","year":"2006","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.672319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T14:57:04Z","timestamp":1623682624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.672319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":79,"alternative-id":["10.3389\/fendo.2021.672319"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.672319","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"article-number":"672319"}}